In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
All content for Talking Rheumatology Research is the property of British Society for Rheumatology and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
Ep 43. The metaverse: a new frontier for rheumatology
Talking Rheumatology Research
11 minutes
1 year ago
Ep 43. The metaverse: a new frontier for rheumatology
Dr Jason E Liebowitz joins Dr Marwan Bukhari to discuss the metaverse and how the field of rheumatology can utilise virtual and augmented reality to improve the lives of patients. Listen now to hear about the current technological developments and what this means for future clinical practice! You can read this article [https://doi.org/10.1093/rheumatology/kead534] in Rheumatology. Thanks for listening to Talking Rheumatology Research! Join the conversation on X using #TalkingRheumResear...
Talking Rheumatology Research
In this episode, recorded live at BSR25, Professor Robert J Moots joins Professor Ernest Choy to discuss their article reporting on a randomized, controlled, head-to-head clinical trial comparing the two most frequently used biologics in active refractory Behçet’s. Listen now to hear the findings and what this means for future clinical practice! Further reading: You can read this article [https://doi.org/10.1093/rheumatology/keae585] in Rheumatology. Thanks for listening to T...
